Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Boerner

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|January 12, 2008
Lung cancer screening with low-dose computed tomography: Canadian experienceHeidi C Roberts, Demetris Patsios, Narinder S Paul, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2009
Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experienceRavi J Menezes, Heidi C Roberts, Narinder S Paul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancerHumberto Lara-Guerra, Thomas K Waddell, Maria A Salvarrey, et al.
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Cancer Treatment and Research Communications|March 12, 2022
Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare systemKirstin Perdrizet, Tracy L Stockley, Jennifer H Law, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 5, 2019
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)Carol C Cheung, Penny Barnes, Gilbert Bigras, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Cancer Research Communications|March 27, 2023
Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent <i>IDH1-</i> and <i>IDH2</i>-mutant GliomaKristina Fanucci, Mary Jo Pilat, Derek Shyr, et al.
Canadian Association of Radiologists Journal = Journal L'Association Canadienne Des Radiologistes|January 12, 2008
Lung cancer screening with low-dose computed tomography: Canadian experienceHeidi C Roberts, Demetris Patsios, Narinder S Paul, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2009
Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experienceRavi J Menezes, Heidi C Roberts, Narinder S Paul, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2009
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancerHumberto Lara-Guerra, Thomas K Waddell, Maria A Salvarrey, et al.
British Journal of Cancer|December 22, 2023
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinomaMichael Cecchini, James M Cleary, Yu Shyr, et al.
Cancer Treatment and Research Communications|March 12, 2022
Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare systemKirstin Perdrizet, Tracy L Stockley, Jennifer H Law, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|October 5, 2019
Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP)Carol C Cheung, Penny Barnes, Gilbert Bigras, et al.
Pageof 3